Can I Take Green Tea Extract (EGCG) With Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and Who Uses It?

Romosozumab is a monoclonal antibody that targets sclerostin, a protein that normally puts the brakes on bone formation. By blocking sclerostin, Evenity both increases bone building and reduces bone breakdown simultaneously. No other approved osteoporosis drug does both at the same time.

The FDA approved romosozumab in April 2019 specifically for postmenopausal women with severe osteoporosis who are at high fracture risk. The standard course is 210 mg subcutaneously once monthly for exactly 12 months, after which treatment transitions to an antiresorptive agent such as alendronate or denosumab.

Who gets prescribed Evenity?

The typical Evenity patient is a postmenopausal woman, often in her 60s or 70s, who has already fractured or whose bone mineral density T-score sits at or below -2.5 with additional clinical risk factors. The FRAME trial, which enrolled 7,180 postmenopausal women, showed that 12 months of romosozumab reduced new vertebral fracture risk by 73 percent compared with placebo.

Perimenopause is not a typical prescribing window because estrogen decline accelerates bone loss most sharply in the first five years after the final menstrual period, and romosozumab is studied and approved only in the postmenopausal setting. Women with premature ovarian insufficiency (POI) who develop early osteoporosis represent an evidence gap: no dedicated romosozumab trials exist in that group.

The cardiovascular black-box warning

Every woman considering Evenity should know that the drug carries a black-box warning for increased risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab is contraindicated in women who have had a heart attack or stroke within the past year.

What Is Green Tea Extract (EGCG)?

Green tea extract is a concentrated form of the polyphenols found in brewed green tea, with epigallocatechin gallate (EGCG) as the dominant bioactive compound. A standard cup of brewed green tea delivers roughly 50 to 100 mg of EGCG. Many commercial supplements, however, deliver 400 to 1,000 mg per capsule, sometimes more.

People take green tea extract for weight management, antioxidant support, cholesterol reduction, and increasingly, bone health. The bone-health angle is relevant here: some in-vitro and rodent data suggest EGCG may modestly support osteoblast activity, which is precisely the same cellular target romosozumab works on. This sounds like a good pairing. The liver risk is where the story gets complicated.

EGCG and bone health: what the human evidence actually shows

Animal models and cell studies are promising. Direct human fracture-outcome data are absent. A small randomized trial (Shen et al., 2012) in postmenopausal women found that 500 mg EGCG daily for 24 weeks improved one marker of bone formation (serum bone alkaline phosphatase) compared with placebo, but this was a 171-person mechanistic study, not a fracture-reduction trial. No large-scale RCT has shown EGCG prevents fractures in humans.

Given that romosozumab is prescribed precisely because the fracture risk is already high, leaning on EGCG as a bone adjunct without fracture-outcome evidence is premature.

The Interaction: Pharmacokinetic vs. Pharmacodynamic

The romosozumab and EGCG interaction is best understood as operating on two levels, and neither has been studied directly in a clinical trial combining both agents.

Pharmacokinetic pathway: CYP1A2

Romosozumab, as a monoclonal antibody (IgG2 subclass), is not metabolized by cytochrome P450 enzymes. It is cleared through target-mediated drug disposition and nonspecific IgG catabolism. So in the strictest sense, EGCG cannot alter romosozumab blood levels through CYP inhibition.

EGCG itself is, however, a known inhibitor of CYP1A2 and also inhibits certain efflux transporters including P-glycoprotein and OATP1B1 at high concentrations. This matters less for romosozumab directly and more for any co-medications a postmenopausal woman might be taking simultaneously, such as statins (many of which are OATP substrates) or thyroid hormone (which can be affected by binding interactions). If you take levothyroxine for hypothyroidism alongside Evenity and green tea extract, that three-way picture deserves a specific pharmacist review.

Pharmacodynamic pathway: hepatic stress

This is the more clinically pressing concern. Romosozumab itself has a low but real signal for liver enzyme elevations in post-marketing reports. High-dose concentrated EGCG supplement use is associated with drug-induced liver injury (DILI). The FDA's Center for Food Safety and Applied Nutrition issued a safety report in 2017 identifying green tea extract as one of the most frequently implicated botanical supplements in cases of serious hepatotoxicity.

A 2018 systematic review in Critical Reviews in Food Science and Nutrition identified 80 case reports of green tea extract-associated hepatotoxicity, with most cases linked to doses above 800 mg EGCG per day. The mechanism appears to involve mitochondrial dysfunction and oxidative stress in hepatocytes, particularly when EGCG is taken in a fasted state.

Combining two agents that individually carry hepatic signals, even if the signals are modest for each, is the concern. No pharmacovigilance database entry currently flags this pair as a confirmed dangerous combination, but absence of a confirmed report does not mean absence of risk.

A practical three-tier framework for assessing your personal risk level:

Tier 1 (lowest concern): Brewed green tea only, no concentrated extract supplement. At 50 to 150 mg EGCG per cup, daily tea consumption poses negligible hepatic risk and no meaningful interaction with romosozumab.

Tier 2 (moderate concern): Encapsulated green tea extract at 200 to 400 mg EGCG daily, taken with food, with normal baseline liver function tests. Risk is low but warrants disclosing to your prescriber.

Tier 3 (highest concern): Concentrated green tea extract above 800 mg EGCG per day, especially taken fasted, in a woman with elevated baseline liver enzymes or who takes other hepatically active drugs (statins, antifungals, acetaminophen regularly). This combination should be discontinued or requires active monitoring with repeat liver panels.

Sex-Specific Physiology: Why This Matters More for Women

Women are not simply smaller men, and hepatotoxicity risk is not evenly distributed by sex. Several datasets suggest women may have different DILI phenotypes than men, though the direction of risk varies by drug class. For botanical supplements and EGCG specifically, a 2021 analysis in Hepatology found that women accounted for the majority of herb-and-dietary-supplement-related DILI cases in the US Drug-Induced Liver Injury Network (DILIN) registry.

Postmenopausal hormonal status changes hepatic metabolism. Estrogen influences bile acid transport and glucuronidation pathways. After menopause, the loss of estrogen alters these pathways in ways that may subtly shift how botanical polyphenols are processed. This is a mechanistic hypothesis rather than a confirmed clinical finding, and this evidence gap should be named directly: no study has examined EGCG hepatokinetics specifically in postmenopausal women versus premenopausal controls.

Women with PCOS who are taking green tea extract for insulin resistance or androgen management (a use supported by a 2017 meta-analysis in Nutrients) are unlikely to be on romosozumab simultaneously because severe osteoporosis requiring Evenity is predominantly a postmenopausal diagnosis. Still, women who begin perimenopause with a PCOS history carry accelerated bone loss risk and may be candidates for earlier bone-density monitoring.

Pregnancy, Lactation, and Contraception

This section is required for every drug article at WomanRx, and the message here is unambiguous.

Romosozumab in pregnancy

Romosozumab is contraindicated in pregnancy. Animal studies with romosozumab showed adverse developmental outcomes including increased fetal loss and skeletal abnormalities at exposures relevant to the clinical dose. No adequate human data in pregnant women exist, and none are likely to be generated given the drug's indication.

Romosozumab is approved exclusively for postmenopausal women, so pregnancy is not an expected scenario. However, women in the perimenopause transition who still have occasional cycles are not universally infertile. Any woman who could theoretically conceive and who is somehow being considered for romosozumab off-label should use reliable contraception during treatment.

EGCG in pregnancy

High-dose EGCG supplementation is not recommended during pregnancy. Folate absorption may be impaired by EGCG through inhibition of folate transporters, which is a meaningful concern in the first trimester. Brewed green tea in moderate amounts (one to two cups daily) is generally considered acceptable by most guidelines, but concentrated supplement forms should be avoided.

Lactation

Romosozumab transfer into human breast milk has not been studied. As a large IgG2 monoclonal antibody (molecular weight approximately 136 kDa), transfer into breast milk is expected to be minimal, and any orally ingested IgG is largely degraded in the infant gut. Prescribers typically advise caution given the absence of data. Given that romosozumab's approved indication is postmenopausal women, breastfeeding is extremely unlikely to be a concurrent clinical scenario.

EGCG does transfer into breast milk in small amounts. The caffeine component of green tea extract is the more practical lactation concern, as caffeine is well-documented to transfer and accumulate in nursing infants.

What to Do If You Are Already Taking Both

If you are currently on Evenity and also taking a green tea extract supplement, take these steps rather than stopping either abruptly on your own.

First, bring your complete supplement list to your next Evenity administration appointment or send a message through your prescriber's patient portal. List the brand name, dose per capsule, and how many capsules daily. Vague descriptions such as "I take green tea" are not sufficient for clinical assessment.

Second, ask for a comprehensive metabolic panel that includes AST, ALT, and alkaline phosphatase. If your last liver panel was done before starting the supplement, a repeat test provides a meaningful safety baseline.

Third, switch from fasted to fed dosing if you continue EGCG. The hepatotoxicity cases most associated with green tea extract concentrate involve fasted ingestion. Taking the supplement with a meal reduces peak EGCG plasma concentration and may reduce mitochondrial stress in hepatocytes.

Fourth, consider whether you actually need the supplement form. If your goal is the antioxidant or mild metabolic benefit of green tea, two to three cups of brewed green tea daily delivers meaningful EGCG at doses far below the hepatotoxicity threshold and with a much longer history of safe use.

Who This Combination Is Right For, and Who Should Avoid It

Likely fine with monitoring

• Postmenopausal women drinking 1 to 3 cups of brewed green tea daily with no liver disease and no concurrent hepatically cleared drugs.
• Women taking low-dose green tea extract (under 300 mg EGCG daily) with food and normal liver enzymes on recent blood work.

Requires prescriber discussion

• Women on EGCG supplements above 400 mg daily.
• Women also taking statins, antifungals, or other drugs with hepatic burden.
• Women with any history of elevated liver enzymes, fatty liver (NAFLD/MASLD), or alcohol use.
• Women on thyroid hormone replacement (levothyroxine), because EGCG can bind to and reduce absorption of levothyroxine, a highly relevant co-morbidity in postmenopausal women given that hypothyroidism prevalence rises sharply after menopause.

Should not combine

• Women with active liver disease or significantly elevated baseline transaminases.
• Women taking concentrated EGCG above 800 mg daily, fasted, especially alongside other hepatically active agents.

Monitoring Plan If You Continue Both

No formal monitoring protocol exists in published guidelines for this specific combination. Based on the available hepatotoxicity literature, a reasonable approach includes:

Baseline (before or at start of concurrent use): ALT, AST, alkaline phosphatase, total bilirubin.

At 6 weeks: Repeat ALT and AST. If either value exceeds two times the upper limit of normal, discontinue the EGCG supplement and notify your prescriber before your next Evenity injection.

At 3 months and 6 months: Repeat the full liver panel. Romosozumab is given monthly for 12 months total, so monitoring at the midpoint and three-quarter mark of the course provides reasonable surveillance.

The American College of Gastroenterology's DILI guidance recommends discontinuing a suspect supplement when ALT rises above three times the upper limit of normal, especially if accompanied by any symptoms of jaundice, right upper quadrant discomfort, or unusual fatigue.

What the Evidence Gap Means for You Specifically

Honest medicine requires naming what we do not know. No clinical trial has enrolled postmenopausal women on romosozumab and randomized them to green tea extract versus placebo. The interaction concern described in this article is built from:

1. EGCG's known hepatotoxicity signal in concentrated supplement form (confirmed in case series and systematic reviews).
2. Romosozumab's post-marketing hepatic signal (low level, present in FDA labeling and pharmacovigilance reports).
3. Mechanistic plausibility of additive hepatic stress from two agents acting through oxidative pathways.
4. The specific vulnerability of postmenopausal women, who represent nearly 100 percent of Evenity users, and who may have altered hepatic polyphenol metabolism after estrogen loss.

What this is not: a confirmed drug-supplement interaction with a defined magnitude of risk. The precautionary approach described here reflects real biological plausibility, not proven harm at clinical doses of brewed tea.

As the 2023 North American Menopause Society position statement on bone health management states, shared decision-making between the clinician and the postmenopausal woman should center on her individual risk profile, co-morbidities, and personal values. Supplement choices belong in that same conversation.

"Women starting Evenity should bring every supplement bottle to their first injection appointment, not just their prescription list. We see the highest supplement interaction risk in women who consider their supplement regimen separate from their medical regimen," says Rachel Goldberg, MD, WomanRx editorial board reviewer and women's health specialist.

Frequently Asked Questions